Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model
Journal
PloS one
Journal Volume
17
Journal Issue
2
Date Issued
2022
Author(s)
Abstract
Myocardial dysfunction is a major cause of poor outcomes in the post-cardiac arrest period. Omecamtiv mecarbil (OM) is a selective small molecule activator of cardiac myosin that prolongs myocardial systole and increases stroke volume without apparent effects on myocardial oxygen demand. OM administration is safe and improves cardiac function in patients with acute heart failure. Whether OM improves post-resuscitation myocardial dysfunction remains unclear. This study investigated the effect of OM treatment on post-resuscitation myocardial dysfunction and outcomes.
SDGs
Type
journal article